Vivanza Biosciences Quarterly Results for Trading Insights
In Sept 2025, Vivanza Biosciences (VIVANZA) reported revenue ₹55 Cr and net profit ₹1 Cr — revenue +1733.3% YoY. For annual financials, live price and key ratios, visit Vivanza Biosciences share price today.
VIVANZA Quarterly Results — Revenue, Profit & EPS Highlights
Vivanza Biosciences latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Compare with VIVANZA fair price to assess whether the stock is under or overvalued.
- Revenue of ₹55 Cr in Sept 2025 (+5400.0% vs Mar 2025, +1733.3% vs Sept 2024)
- Net Profit of ₹1 Cr in Sept 2025 (+200.0% vs Mar 2025)
- EBITDA of ₹1 Cr in Sept 2025 (+200.0% vs Mar 2025)
- Operating Margin of 1.0% in Sept 2025 (+201.0pp vs Mar 2025)
- Earnings Per Share of ₹0.14 in Sept 2025 (+156.0% vs Mar 2025)
Vivanza Biosciences Quarterly Results — Revenue, EBITDA, Net Profit & EPS
VIVANZA quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2025 | Mar 2025 | Jun 2025 | Sept 2024 | Mar 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 55 | 1 | 9 | 3 | 4 | 5400.0% | 1733.3% |
| Net Profit (₹ Cr) | 1 | -1 | 0 | 0 | 0 | - | - |
| EBITDA (₹ Cr) | 1 | -1 | 0 | 0 | 0 | - | - |
| EPS (₹) | 0.14 | -0.25 | 0.02 | 0.00 | -0.10 | - | - |
| Operating Margin (%) | 1.0% | -200.0% | 2.0% | 4.0% | -3.0% | - | - |
VIVANZA Share Price Trend — 1-Year Movement Across Quarterly Results
Vivanza Biosciences 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Analyse VIVANZA shareholder distribution to track promoter, FII and institutional holdings.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
VIVANZA vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Vivanza Biosciences latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2025 |
₹396,418.12 Cr | 1675.5 | 14,875 | 3,125 | +10.8% | - | 21.0% | 128.9 |
|
Divis Laboratories
Sept 2025 |
₹161,139.43 Cr | 6229.0 | 2,860 | 689 | +7.1% | - | 24.1% | 239.9 |
|
Torrent Pharmaceuti…
Sept 2025 |
₹140,630.85 Cr | 4179.5 | 3,219 | 591 | +11.3% | - | 18.4% | 238.3 |
|
Lupin
Sept 2025 |
₹106,664.75 Cr | 2326.1 | 6,921 | 1,485 | +23.2% | - | 21.5% | 71.9 |
|
Dr Reddys Laborator…
Sept 2025 |
₹103,153.53 Cr | 1235.7 | 9,135 | 1,337 | +1.1% | - | 14.6% | 76.4 |
All amounts in ₹ Crores